TG Therapeutics (0VGI) Price & Analysis
0VGI Stock Chart & Stats
- Day’s Range
- $56.70 - $56.70
- 52-Week Range
- $30.39 - $56.70
- Previous Close
- $56.70
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- $9.36B
- Enterprise Value
- $8.84B
- Total Cash (Recent Filing)
- $552.25M
- Total Debt (Recent Filing)
- $754.44M
- Price to Earnings (P/E)
- 20.1
- Beta
- 0.06
- Next Earnings
- Nov 09, 2026
- EPS Estimate
- 0.37
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
BRIUMVI Commercial Growth
Rapid BRIUMVI adoption, rising patient starts and expanding physician use are establishing a stronger commercial base. The higher guidance and planned 2027 $1B+ U.S. revenue year indicate meaningful franchise momentum beyond a single quarter.
High Gross Margins And Profitability
The product’s high gross margin and recent operating profitability provide operating leverage as sales expand. This supports reinvestment in commercialization and development, although reported earnings should still be assessed against weaker cash conversion.
BRIUMVI Lifecycle Expansion
A successful subcutaneous formulation could broaden BRIUMVI’s addressable market beyond physician-administered treatment and improve convenience. Alongside the positive ENHANCE trial, it may strengthen retention, switching potential and the product’s competitive longevity.
Bears Say
Weak Cash Conversion
Persistent negative operating and free cash flow despite reported profitability raises questions about earnings quality, working-capital timing and cash realization. Continued weak conversion could limit internally funded investment and make reported income less durable.
Competitive And Rebate Pressure
Rival anti-CD20 therapies can constrain market share, pricing and prescribing momentum as BRIUMVI scales. Material rebates and chargebacks further reduce realized revenue, creating a lasting risk that strong gross sales will translate into lower net economics.
Manufacturing Cost Burden
Manufacturing investments for the subcutaneous and secondary-source programs are depressing reported profitability and may continue through 2026. Although they could support future supply and product expansion, execution delays would leave TG with substantial costs before benefits arrive.
TG Therapeutics News
0VGI FAQ
What was TG Therapeutics’s price range in the past 12 months?
What is TG Therapeutics’s market cap?
When is TG Therapeutics’s upcoming earnings report date?
How were TG Therapeutics’s earnings last quarter?
Is TG Therapeutics overvalued?
Does TG Therapeutics pay dividends?
What is TG Therapeutics’s EPS estimate?
How many shares outstanding does TG Therapeutics have?
What happened to TG Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of TG Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
TG Therapeutics Stock Smart Score
Company Description
TG Therapeutics
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael S. Weiss
- Employees
- 399
- Website
- www.tgtherapeutics.com
- Address
- 3020 Carrington Mill Blvd., Morrisville, NY, 27560, US
TG Therapeutics (0VGI) Earnings & Revenues
0VGI Earnings Call
Earnings Call SentimentPositive
The call communicated strong commercial momentum, robust Q2 financial results, multiple positive clinical/readout milestones (ENHANCE Phase III positive; subcutaneous program advancing), growing real-world evidence, and a healthy cash position — all of which underpin upgraded guidance and an optimistic multi-year franchise opportunity. Near-term headwinds include sizable manufacturing-related charges expensed now (with potential future margin tailwinds if programs succeed), seasonality/timing risk concentrated in Q4, uncertainty around subcutaneous pricing/reimbursement, and ongoing competitive dynamics. On balance, the positive operational and clinical developments and the guidance raise materially outweigh the near-term expenses and execution risks.
View all GB:0VGI earnings summaries0VGI Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 2 | 2 |
| Technical Analysis | 2 | 0 | 1 |
| Moving Averages | 9 | 2 | 1 |